Jennifer Anthony, APRN
Acute Care · Akron, OHNPI 1811565286
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 416 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 32.4% of the total. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 416 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$650
- Madrigal Pharmaceuticals$564
- Pfizer$364
- Aimmune Therapeutics, Inc.$321
- plus $3K from 27 others
What the payments were for
- Food & beverage$8,97299%
- Education$841%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 136 | $2,932 |
| Johnson & Johnson | 49 | $1,219 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $650 |
| Madrigal Pharmaceuticals | 7 | $564 |
| Pfizer | 17 | $364 |
| Aimmune Therapeutics, Inc. | 12 | $321 |
| QOL Medical, LLC | 15 | $305 |
| Bristol Myers Squibb | 21 | $270 |
| Lilly USA, LLC | 15 | $261 |
| Merck | 14 | $257 |
| Phathom Pharmaceuticals, Inc. | 8 | $235 |
| Sanofi | 9 | $227 |
| Nestle Healthcare Nutrition Inc. | 12 | $191 |
| Ardelyx, Inc. | 11 | $188 |
| Regeneron Healthcare Solutions, Inc. | 6 | $147 |
| Ferring Pharmaceuticals Inc. | 9 | $133 |
| Braintree Laboratories, Inc. | 6 | $132 |
| Evoke Pharma, Inc. | 7 | $102 |
| Intercept Pharmaceuticals, Inc. | 5 | $81 |
| Boehringer Ingelheim | 4 | $62 |
| Daiichi Sankyo Inc. | 3 | $56 |
| Ascendis Pharma Endocrinology Inc | 2 | $55 |
| Ironwood Pharmaceuticals, Inc | 3 | $53 |
| Novo Nordisk | 2 | $39 |
| Ipsen Biopharmaceuticals, Inc | 2 | $36 |
| Amgen | 2 | $35 |
| Redhill Biopharma Inc. | 2 | $31 |
| Mylan Institutional Inc. | 1 | $24 |
| Organon | 2 | $19 |
| AstraZeneca | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Celltrion USA Inc. | 1 | $16 |
| Gilead | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,056 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 74 | $54,205 |
| Mesalamine ErMesalamine | 20 | $10,400 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 39 | $6,162 |
| Pantoprazole Sodium | 327 | $4,402 |
| Esomeprazole Magnesium | 57 | $4,012 |
| Omeprazole | 300 | $3,325 |
| Colestipol Hcl | 32 | $2,382 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 18 | $2,040 |
| Sucralfate | 18 | $1,593 |
| Rabeprazole Sodium | 53 | $1,458 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 68 | $1,394 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 21 | $1,390 |
| Famotidine | 106 | $1,210 |
| Lansoprazole | 34 | $919 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 24 | $373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $2,932 | $54,20574 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $132 | $8,20157 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.
Other acute care in Akron
- Sarah SerbAkron$7K
- Angel SaboAkron$6K
- Megan BerarducciAkron$4K
- Andrea RobinsonCleveland$149K
- Brittney BrowneMonroe$142K
- Jamie McGuireMiamisburg$86K
- Ileah ReichertColumbus$73K
- Davida PraterBeavercreek$46K
- Dawn FrenchAlliance$40K
- Holly McKibbenColumbus$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.